Drug intelligence / Profile preview

BEN-2293

Development stage: Phase 2
Lead developer: BenevolentAI
Modality: Small Molecules
Administration: Topical

Overview

BEN-2293 is a **small molecule** drug developed by BenevolentAI. It is a **selective inhibitor of the three tropomyosin-related kinases (Trk) receptors**: TrkA, TrkB, and TrkC, also known as a **pan-Trk inhibitor**. It is formulated for **topical administration** and is being investigated for the treatment of **mild-to-moderate atopic dermatitis**. The drug aims to address inflammation and itch associated with atopic dermatitis by inhibiting itch signaling and blocking nerve sensitization.

Targets

NTRK2 (Tropomyosin-related kinase receptor type B)NTRK3 (Tropomyosin receptor kinase C)NTRK1 (Tropomyosin-related receptor kinase A)

Beyond the preview

Go deeper on BEN-2293.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BEN-2293.

Explore the full profile